Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-dependent Chronic Kidney Disease
Status: Enrolling
Updated:  10/3/2017
AMAG Pharmaceuticals, Inc.
mi
from
Waltham, MA
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-dependent Chronic Kidney Disease
Status: Enrolling
Updated: 10/3/2017
AMAG Pharmaceuticals, Inc.
mi
from
Waltham, MA
Click here to add this to my saved trials
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease
Status: Enrolling
Updated:  10/3/2017
AMAG Pharmaceuticals, Inc.
mi
from
Waltham, MA
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease
Status: Enrolling
Updated: 10/3/2017
AMAG Pharmaceuticals, Inc.
mi
from
Waltham, MA
Click here to add this to my saved trials
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.
Status: Enrolling
Updated:  10/4/2017
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.
Status: Enrolling
Updated: 10/4/2017
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Louisville
mi
from
Louisville, KY
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
NHLBI
mi
from
Bethesda, MD
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
NHLBI
mi
from
Bethesda, MD
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Akron Children's Hospital
mi
from
Akron, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Texas Children's Hospital
mi
from
Houston, TX
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Texas Southwestern
mi
from
Dallas, TX
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Charlotte, NC
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Durham, NC
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated:  10/5/2017
Emory Transplant Center
mi
from
Atlanta, GA
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated: 10/5/2017
Emory Transplant Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated:  10/5/2017
Northwestern University (Kovler Transplant Center)
mi
from
Chicago, IL
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated: 10/5/2017
Northwestern University (Kovler Transplant Center)
mi
from
Chicago, IL
Click here to add this to my saved trials
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated:  10/5/2017
Columbia University Medical Center
mi
from
New York, NY
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Status: Enrolling
Updated: 10/5/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
The Pathogenesis of Chronic Graft Failure After Kidney Transplantation
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
The Pathogenesis of Chronic Graft Failure After Kidney Transplantation
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation
Influence of MDR-1 CYP3A4 and CYP3A5 Genotypes/Haplotypes on Sirolimus Pharmacokinetics and Pharmacodynamics in Patients With Renal Transplantation
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation
Influence of MDR-1 CYP3A4 and CYP3A5 Genotypes/Haplotypes on Sirolimus Pharmacokinetics and Pharmacodynamics in Patients With Renal Transplantation
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Jacksonville, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Austin, TX
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Azusa, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Azusa, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Bakersfield, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Chino, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Chino, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Los Angeles, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
North Hollywood, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
North Hollywood, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Orange, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Riverside, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
San Dimas, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
San Dimas, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
West Hills, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
West Hills, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Yuba City, CA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Yuba City, CA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Denver, CO
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Daytona Beach, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Edgewater, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Edgewater, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Miami, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Ocala, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Ocala, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Port Charlotte, FL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Savannah, GA
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Evanston, IL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Evanston, IL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gurnee, IL
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gurnee, IL
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Detroit, MI
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Asheville, NC
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Wilmington, NC
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Columbus, OH
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials